Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 1, 2009, Pages 162-173

  La Porte, Charles J L ^a,d   Sabo, John P ^b   Elgadi, Mabrouk ^c   Cameron, D William ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; FLUCONAZOLE; RIFABUTIN; RITONAVIR PLUS TIPRANAVIR;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG ERUPTION; DRUG INTERACTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS; LOADING DRUG DOSE; LOOSE FECES; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; TASTE DISORDER; TASTE PERVERSION; VERTIGO; VOMITING;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CLARITHROMYCIN; DRUG INTERACTIONS; FEMALE; FLUCONAZOLE; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PYRIDINES; PYRONES; RIFABUTIN; RITONAVIR;

EID: 59749093533     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00534-08     Document Type: Article

References (26)

1. Apseloff, G. 2003. Severe neutropenia among healthy volunteers given rifabutin in clinical trials. Clin. Pharmacol. Ther. 74:591-593.
2. Boruchoff, S. E., M. G. Sturgill, K. W. Grasing, J. R. Seibold, J. McCrea, G. A. Winchell, S. E. Kusma, and P. J. Deutsch. 2000. The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin. Clin. Pharmacol. Ther. 67:351-359.
3. Brophy, D. F., D. S. Israel, A. Pastor, C. Gillotin, G. E. Chittick, W. T. Symonds, Y. Lou, B. M. Sadler, and R. E. Polk. 2000. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. Antimicrob. Agents Chemother. 44:978-984.
4. Burman, W. J., K. Gallicano, and C. Peloquin. 2001. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 40:327-341.
5. Cato, A., III, G. Cao, A. Hsu, J. Cavanaugh, J. Leonard, and R. Granneman. 1997. Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir. Drug Metab. Dispos. 25:1104-1106.
6. Cato, A., III, J. Cavanaugh, H. Shi, A. Hsu, J. Leonard, and R. Granneman. 1998. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin. Pharmacol. Ther. 63:414-421.
7. Cooper, C., R. van Heeswijk, M. Bilodeau, B. Kovacs, J. Sabo, T. MacGregor, J. Wruck, M. Elgadi, D. Neubacher, and S. McCallister. 2005. The pharmacokinetics (PK) of single-dose and steady-state tipranavir/ritonavir (TPV/r) 500 mg/200 mg in subjects with mild or moderate hepatic impairment, abstr. 3.11. Sixth Int. Workshop Clin. Pharmacol. HIV Ther., Montreal, Quebec, Canada, 28 to 30 April 2005.
8. De Wit, S., M. Debier, M. De Smet, J. McCrea, J. Stone, A. Carides, C. Matthews, P. Deutsch, and N. Clumeck. 1998. Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 42:223-227.
9. Egger, M., M. May, G. Chene, A. N. Phillips, B. Ledergerber, F. Dabis, D. Costagliola, A. D'Arminio Monforte, F. de Wolf, P. Reiss, J. D. Lundgren, A. C. Justice, S. Staszewski, C. Leport, R. S. Hogg, C. A. Sabin, M. J. Gill, B. Salzberger, and J. A. Sterne. 2002. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360:119-129.
10. Flexner, C., and P. Barditch-Crovo. 2003. Severe neutropenia among healthy volunteers given rifabutin in clinical trials. Clin. Pharmacol. Ther. 74:592-593.
11. Gallicano, K., Y. Khaliq, G. Carignan, A. Tseng, S. Walmsley, and D. W. Cameron. 2001. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. 70:149-158.
12. Koks, C. H., K. M. Crommentuyn, R. M. Hoetelmans, D. M. Burger, P. P. Koopmans, R. A. Mathot, J. W. Mulder, P. L. Meenhorst, and J. H. Beijnen. 2001. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals. Br. J. Clin. Pharmacol. 51:631-635.
13. MacGregor, T. R., J. P. Sabo, S. H. Norris, P. Johnson, L. Galitz, and S. McCallister. 2004. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin. Trials 5:371-382.
14. Olkkola, K. T., J. Ahonen, and P. J. Neuvonen. 1996. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth. Analg. 82:511-516.
15. Ouellet, D., A. Hsu, G. R. Granneman, G. Carlson, J. Cavanaugh, H. Guenther, and J. M. Leonard. 1998. Pharmacokinetic interaction between ritonavir and clarithromycin. Clin. Pharmacol. Ther. 64:355-362.
16. Peloquin, C. A. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169-2183.
17. Polk, R. E., D. F. Brophy, D. S. Israel, R. Patron, B. M. Sadler, G. E. Chittick, W. T. Symonds, Y. Lou, D. Kristoff, and D. S. Stein. 2001. Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob. Agents Chemother. 45:502-508.
18. Pukenyte, E., F. X. Lescure, D. Rey, C. Rabaud, B. Hoen, P. Chavanet, A. P. Laiskonis, J. L. Schmit, T. May, Y. Mouton, and Y. Yazdanpanah. 2007. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment. Int. J. Tuberc. Lung Dis. 11:78-84.
19. Raffi, F., M. Battegay, S. Rusconi, M. Opravil, G. Blick, R. T. Steigbigel, M. Kraft, D. Neubacher, and J. P. Sabo. 2007. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. AIDS 21:1977-1980. (Erratum, 22:i, 2008.)
20. + patients receiving TPV 500 mg bid coadministered with RTV 100 mg or 200 mg bid, abstr. 7. Eighth Int. Workshop Clin. Pharmacol. HIV Ther., Budapest, Hungary.
21. Schwiesow, J. N., M. D. Iseman, and C. A. Peloquin. 2008. Concomitant use of voriconazole and rifabutin in a patient with multiple infections. Pharmacotherapy 28:1076-1080.
22. Spradling, P., D. Drociuk, S. McLaughlin, L. M. Lee, C. A. Peloquin, K. Gallicano, C. Pozsik, I. Onorato, K. G. Castro, and R. Ridzon. 2002. Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak. Clin. Infect. Dis. 35:1106-1112.
23. Stein, C. M. 2003. Managing risk in healthy subjects participating in clinical research. Clin. Pharmacol. Ther. 74:511-512.
24. van Heeswijk, R., J. P. Sabo, C. Cooper, W. Cameron, T. R. MacGregor, M. Elgadi, F. Harris, S. McCallister, and D. Mayers. 2004. The pharmacokinetic interaction between tipranavir/ritonavir 500 mg/200 mg bid (tipranavir/r) and atorvastatin, antacid and CYP3A4 in healthy volunteers, abstr. 5.2. Fifth Int. Workshop Clin. Pharmacol. HIV Ther., Rome, Italy.
25. van Heeswijk, R., J. Sabo, T. MacGregor, M. Elgadi, F. Harris, S. McCallister, and D. Mayers. 2004. The pharmacokinetic interaction between single-dose rifabutin and steady-state tipranavir/ritonavir 500 mg/200 mg (TPV/r) in healthy volunteers, abstr. A-456. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
26. Williams, R. L., M. L. Chen, and W. W. Hauck. 2002. Equivalence approaches. Clin. Pharmacol. Ther. 72:229-237.